AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
20:16
Carlos Alcaraz, the first finalist of the Vienna tournament. The tennis player managed to defeat Daniil Medvedev in the semifinals
19:49
Minister of National Defence, first reaction after two drones entered Romania’s airspace without authorization: “I am up to date with the developments in the security situation in northeastern Romania / Monitoring and intervention actions are underway”
19:30
Russia warned by the US about a possible terrorist attack on Moscow’s Tsaritsyno Palace / FSB assured that it would take appropriate measures
19:13
The Prime Minister of Ethiopia sent his entire cabinet of ministers for military training
18:35
French Ministry of the Interior: 15,000 protesters at the “Act 3” of the social mobilization
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
